Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Veru Inc. is a clinical-stage biopharmaceutical company focused on developing oncology and acute care therapeutics. The company's lead asset, sabizabulin, is an oral microtubule disruptor being evaluated for metastatic prostate cancer and previously studied for COVID-19 acute respiratory distress syndrome. With no commercial revenue and negative operating cash flow, Veru is a binary-outcome clinical development story dependent on regulatory milestones and capital markets access.
Veru operates as a pure clinical development entity following divestiture of commercial assets. The business model centers on advancing sabizabulin through Phase 3 oncology trials, securing FDA approval, and either commercializing directly in select markets or partnering with larger pharmaceutical companies for global distribution. Value creation depends entirely on clinical trial success, regulatory approval probability, and eventual market penetration in competitive oncology indications. The company has no pricing power until regulatory approval and faces binary risk on each clinical readout.
Sabizabulin Phase 3 clinical trial data readouts and interim analyses in metastatic prostate cancer
FDA regulatory interactions, including meeting outcomes, clinical hold resolutions, and approval pathway clarity
Capital raises and cash runway extensions - dilution events or non-dilutive financing announcements
Strategic partnership announcements or licensing deals that validate platform or provide non-dilutive funding
Competitive landscape shifts in prostate cancer treatment (novel androgen receptor inhibitors, PARP inhibitors, radiopharmaceuticals)
Binary clinical trial risk - single asset dependency on sabizabulin creates total loss potential if Phase 3 trials fail to meet endpoints or encounter safety issues
Regulatory pathway uncertainty - FDA's evolving standards for oncology approvals and potential requirement for additional trials extends timeline and capital needs
Competitive intensity in prostate cancer - crowded landscape with Pfizer's Xtandi, J&J's Zytiga, Novartis' Pluvicto, and emerging ADC therapies limits commercial opportunity even with approval
Established prostate cancer franchises with strong clinical data and market penetration create high bar for sabizabulin differentiation
Well-funded competitors (Clovis Oncology, Myovant Sciences, Point Biopharma) advancing alternative mechanisms in same indication
Potential for competitive trial data to reset efficacy expectations or reveal superior safety profiles before sabizabulin readout
Cash runway risk - with negative $40-50M annual operating cash flow and minimal revenue, company faces recurring dilution or potential insolvency if unable to access capital markets
Equity dilution overhang - market cap near zero with ongoing funding needs means existing shareholders face severe dilution in future raises
Going concern risk - auditors may flag substantial doubt about ability to continue operations if cash position deteriorates without clear financing path
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, capital markets access for funding is highly sensitive to risk appetite and biotech sector sentiment, which correlates with broader economic conditions. Recession environments typically compress biotech valuations and restrict financing options.
Rising interest rates negatively impact Veru through two channels: (1) higher discount rates compress NPV of distant future cash flows from potential drug approvals, disproportionately affecting pre-revenue biotechs, and (2) tighter financial conditions reduce speculative capital available for clinical-stage companies. The 2022-2023 rate hiking cycle contributed to biotech sector compression. Current ratio of 5.16x provides liquidity buffer, but future capital raises become more dilutive in high-rate environments.
Minimal direct credit exposure given low debt/equity ratio of 0.08x. However, the company is highly dependent on equity capital markets for survival. Credit market stress that spills into equity markets or reduces institutional risk appetite directly threatens the ability to raise necessary funding for clinical operations.
momentum - Attracts highly speculative biotech investors and event-driven traders focused on binary clinical catalysts. The -57.4% one-year return and -34.5% six-month return reflect typical pre-revenue biotech volatility. Institutional ownership likely minimal given market cap near zero. Investor base consists primarily of retail speculators, dedicated biotech funds willing to accept binary risk, and potentially distressed/special situations investors if company approaches financial stress.
high - Clinical-stage biotechs with single-asset dependency exhibit extreme volatility around data readouts, regulatory decisions, and financing events. Stock can move 30-50%+ on single news items. Recent 57% annual decline demonstrates downside volatility, while any positive clinical data could generate triple-digit percentage moves. Illiquidity from small market cap amplifies price swings.